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Abstract
Genetic testing of patients with cancer is increasingly offered to guide management, resulting in a growing need for
oncology health professionals to communicate genetics information and facilitate informed decision-making in a short time
frame. This scoping review aimed to map and synthesise what is known about health professionals’ communication about
genetic testing for hereditary breast and ovarian cancer with cancer patients. Four databases were systematically searched
using a recognised scoping review method. Areas and types of research were mapped and a narrative synthesis of the
ﬁndings was undertaken. Twenty-nine papers from 25 studies were included. Studies were identiﬁed about (i) information
needs, (ii) process and content of genetic counselling, (iii) cognitive and emotional impact, including risk perception and
recall, understanding and interpretation of genetic test results, and anxiety and distress, (iv) patients’ experiences,
(v) communication shortly after diagnosis and (vi) alternatives to face-to-face genetic counselling. Patients’ need for cancer-
focused, personalised information is not always met by genetic counselling. Genetic counselling tends to focus on
biomedical information at the expense of psychological support. For most patients, knowledge is increased and anxiety is not
raised by pre-test communication. However, some patients experience anxiety and distress when results are disclosed,
particularly those tested shortly after diagnosis who are unprepared or unsupported. For many patients, pre-test
communication by methods other than face-to-face genetic counselling is acceptable. Research is needed to identify patients
who may beneﬁt from genetic counselling and support and to investigate communication about hereditary breast and ovarian
cancer by oncology health professionals.
Introducton
The increase in genetic testing shortly after diagnosis to
guide breast and ovarian cancer management requires a shift
in pre-test genetic communication, from specialist genetics
to mainstream oncology services. Oncology health
professionals are increasingly required to discuss the
options and possible outcomes of genetic testing with
patients. Alongside this change, genetics health profes-
sionals are required to counsel cancer patients who are
newly diagnosed or receiving palliative care about the
implications of a genetic test result for themselves and their
families. Learning from previous practice and research can
help to inform the development of new approaches to
communicating about genetic testing with cancer patients.
This scoping review aimed to summarise and map the
range, extent and nature of the published research into
communication about hereditary breast and ovarian cancer
between genetics and oncology health professionals and
patients. The purpose of the review was to summarise and
disseminate the research ﬁndings for health professionals,
policy makers and consumers and inform future clinical
practice and research as the shift in genetic testing takes
place.
Two previous reviews investigating studies into the
process and content of genetic counselling concluded that
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genetic counselling is often provider-driven, educational
and biomedical in content with little attention to psycho-
social aspects [1, 2]. These two reviews addressed com-
munication about all types of hereditary conditions,
including women with and at risk of hereditary breast and
ovarian cancer.
A review of the communication goals and needs of
cancer patients identiﬁed unmet communication needs and
concluded that communication outcomes are enhanced
when health professionals attend to patients’ emotional
needs [3]. Systematic reviews have highlighted the inﬂu-
ence of health professionals’ personal characteristics on the
effectiveness of communication with cancer patients [4, 5],
the need for an individualised approach [6] and the
importance of good communication skills [7].
No previous systematic or scoping reviews of commu-
nication about genetic testing or hereditary cancer manage-
ment with breast and ovarian cancer patients were identiﬁed.
Methods
Scoping review methodology
This scoping review was informed by the methodology
developed by key authors in the ﬁeld [8–10]. The procedure
was based on the most recent guidance for conducting
scoping reviews [10, 11].
Review question
The review question was driven by the population, concept
and context of the review [11]: What is known about the
communication that takes place about hereditary cancer
between genetics or oncology health professionals and
patients with breast or ovarian cancer?
Search strategy
A search of MEDLINE, CINAHL, PsycINFO and
EMBASE databases was undertaken for the following
search terms adapted for each database: genetic counselling
or genetic counseling or genetic testing and ovarian, breast
or fallopian tube neoplasms or neoplastic syndromes, her-
editary syndromes or hereditary breast and ovarian cancer
syndrome or BRCA1 or BRCA2. The databases were sear-
ched for studies published between 1994, when the BRCA1
gene was identiﬁed, and October 2017. Forward and
backwards citation searches were undertaken on the Web of
Science and Scopus for included papers.
Article selection
The inclusion and exclusion criteria used for screening the
articles were based on the population, concept and context
of the research question [10, 11] (Table 1). Titles and
abstracts were screened by two independent researchers (CJ
Table 1 Inclusion and exclusion criteria used for screening articles
Included Excluded
Population •Women with a personal history of breast or ovarian cancer
•Health professionals specialising in genetics or oncology, including genetic
counsellors, geneticists, oncologists, surgeons and nurses
•Men with breast/prostate cancer
•Cancers other than breast or ovarian cancer
•Children
• Individuals at risk
Concept •Communication about genetic testing and/or hereditary cancer management
• Process and/or content of verbal or written communication, the information
needed, knowledge understood and recalled or the experience of this
communication
• Participants, contexts, interventions or strategies involving patients, health
professionals, health conditions or communication methods
• Impact of genetic test results
• Studies where ﬁndings for cancer patients were not
presented separately from at-risk women
• Family communication
Context •Qualitative and quantitative original research articles of all designs
published in English
•Genetics or oncology setting
•Communication after completing, prior to or during cancer treatment
• Expected outcomes from literature about at-risk women:
○Ratio of health professional–patient talk
○Accuracy and extent of knowledge/recall
○Met/unmet communication needs
○ Satisfaction
○Distress/anxiety
○ Intention to have a procedure/investigation, for example, genetic testing/
surgery
○ Experience/understanding
○ Communication methods
•Reviews, editorials, chapters and commentaries
• Primary/palliative care setting
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and CP) until a good level of agreement was reached (97%).
Remaining articles were reviewed by CJ and validated by
CP.
Data extraction
Details of the method, participants, sample size and inter-
ventions and outcomes signiﬁcant to the review question
were documented onto a data extraction tool [11] by CJ. In
accordance with scoping review methodology [8], quality
assessment of selected studies was not undertaken.
Data synthesis
The iterative process of data synthesis involved a pre-
liminary synthesis of the study ﬁndings, exploration of
relationships between the studies and summary of the syn-
thesised ﬁndings in narrative form within the areas of study
[12, 13]. To identify themes and develop a preliminary
synthesis of the ﬁndings, the studies were organised
according to the main area of study followed by identiﬁ-
cation of relationships between the studies.
Results
Overview of included studies
The PRISMA ﬂow diagram [14] shows the number of
studies identiﬁed, included and excluded (Fig. 1). No stu-
dies of cancer patients were identiﬁed prior to 2000. Since
2008, more studies have focused on cancer patients only
than on cancer patients and at-risk women combined.
Health professionals were mainly genetic counsellors or
clinical geneticists, although one study included the views
of oncology health professionals. The included studies were
published between 2000 and 2017 and were from the
Australia, North America, Europe and Scandinavia. Most of
the studies involved surveys. The types of participants,
country of origin of the research and qualitative or quanti-
tative research methods for the selected studies are shown in
Table 2. Six areas of research were identiﬁed. Most studies
investigated the cognitive and emotional impact of genetic
counselling and testing. The research areas investigated by
the selected studies are shown in Table 3. Details of the
included studies are shown in Table 4.
Areas of research
Patients’ information needs
Five articles were identiﬁed that addressed the information
needs of cancer patients about hereditary cancer [15–19].
One study found that following pre-test genetic counselling,
cancer patients (n= 69) reported unmet information
needs about their risk of contralateral breast cancer and the
cancer risks for their relatives [15]. Prior to counselling,
77% of the patients wanted information about their own risk
and 98% wanted information about their relatives’ risk.
This information was discussed in <45% of the consulta-
tions [15].
A survey of cancer patients (n= 46) and at-risk women
(n= 33) found that cancer patients reported more unmet
information needs about treatment options, including sur-
gery, screening and chemoprevention [16]. Two qualitative
studies, one with 26 breast cancer patients [18] and one with
22 ovarian cancer patients [17] investigated the actual
and hypothetical information needs of those tested shortly
after diagnosis. The studies identiﬁed a preference for brief,
personalised, positive and straightforward information
without statistics. Most patients considered it important to
have information about the purpose of testing, the impli-
cations for treatment decisions, the time frame for results
and the availability of predictive testing for relatives [17,
18]. A Delphi survey of 16 expert genetics and
cancer health professionals and 16 service users with cancer
and a BRCA1/BRCA2 pathogenic variant agreed that
information about inheritance, genetic testing, cancer risks
and the management of hereditary cancer were key mes-
sages for cancer patients. The implications of genetic
testing for treatment were not considered to be key mes-
sages [19].
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Process and content of genetic counselling
Four articles from two studies addressed the process and
content of genetic counselling communication [15, 20–22].
One of these studies [15, 20, 21] involved a content analysis
of genetic counselling consultations with patients (n= 69)
and at-risk women (n= 89) and seven genetics health pro-
fessionals. Essential information about hereditary breast
cancer was consistently communicated during pre-test
counselling. Emotional concerns were not however always
identiﬁed and genetics health professionals infrequently
facilitated patients’ involvement in consultations [20]. The
percentage of consultations in which speciﬁc cancer risks
were discussed was similar for the cancer patients and the
at-risk women [20]. Health professionals discussed sig-
niﬁcantly more aspects of genetic testing (p < .001), facili-
tated active patient involvement (p < .001) and used more
supportive and counselling behaviours with cancer patients
than with at-risk women (p= .02) [21]. Despite supportive
counselling, 68% of the cancer patients studied did not feel
Table 2 Types of participants, including patients and health professionals (HP), country/continent of research origin and qualitative/quantitative
research methods in selected studies
References in ascending
order according to year of
publication—author [ref.]
Participants Country/continent Methods
Cancer
patients and
at-risk
women
Cancer
patients
only
Genetics
HPs
Oncology
HPs
Europe/
Scandinavia
UK Australia North
America
Qual. Quant.
Metcalfe et al. [16] X X X
Randall et al. [23] X X X
Hallowell et al. [35] X X X
Lobb et al. [21]a X X X X
Butow and Lobb [20]a X X X X
Lobb et al. [15]a X X X X
van Dijk et al. [36] X X X
van Roosmalen et al. [39] X X X
Mancini et al. [31] X X X
Pieterse et al. [22] X X X X
Maheu and Thorne [34] X X X
Vadaparampil et al. [38] X X X
Vos et al. [37] X X X
Pieterse et al. [40] X X X X
Vadaparampil et al. [42] X X X
Vos et al. [24]b X X X
Christie et al. [27] X X X
Meiser et al. [18] X X X
Vos et al. [25]b X X X
Vos et al. [26]b X X X
Gleeson et al. [17] X X X
Sie et al. [43] X X X
Jacobs et al. [33] X X X
Scherr et al. [29] X X X
Quinn et al. [32] X X X
Augestad et al. [41] X X X
Benusiglio et al. [30] X X X
Bredart et al. [28] X X X
Jacobs et al. [19] X X X X X
aPapers from the same Australian study
bPapers from the same Netherlands study
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reassured and 57% felt they could have been helped to cope
better with their situation [15].
The same study also identiﬁed that the risk of a patho-
genic variant was communicated in 13.3% of consultations
with cancer patients undergoing diagnostic testing. With at-
risk women, some of whom were undergoing predictive
testing, the risk of a pathogenic variant was communicated
in 71.8% of consultations [15]. With the cancer patients, the
risk of further cancers in the presence of a pathogenic
variant was discussed in 37.3% of consultations and the risk
of further cancers in the absence of a pathogenic variant
was discussed in 29.3% of consultations [20]. Information
about their own and their relatives’ risks of cancer was
communicated in <45% of consultations [15]. In a separate
study involving a survey and analysis of transcripts of pre-
test genetic counselling with 34 cancer patients and 17 at-
Table 3 Areas of research
References in
ascending order
according to year of
publication—author
[ref.]
Information
needs
Process
and
content
Cognitive and emotional impact Experience Timing of pre-test
communication
Alternatives to
face-to-face
genetic
counselling
Recall and
risk
perception
Understand
and interpret
Anxiety
and
distress
Metcalfe et al. [16] X
Randall et al. [23] X X
Hallowell et al. [35] X X
Lobb et al. [21]a X
Butow and Lobb [20]a X
Lobb et al. [15]a X X
van Dijk et al. [36] X X
van Roosmalen et al.
[39]
X
Mancini et al. [31] X X X
Pieterse et al. [22] X
Maheu and Thorne
[34]
X X
Vadaparampil et al.
[38]
X X
Vos et al. [37] X X
Pieterse et al. [40] X
Vadaparampil et al.
[42]
X
Vos et al. [24]b X
Christie et al. [27] X X X
Meiser et al. [18] X X
Vos et al. [25]b X X
Vos et al. [26]b X
Gleeson et al. [17] X X
Sie et al. [43] X X
Jacobs et al. [33] X
Scherr et al. [29] X X
Quinn et al. [32] X X X X
Augestad et al. [41] X X X
Benusiglio et al. [30] X X X X
Bredart et al. [28] X X
Jacobs et al. [19] X
aPapers from the same Australian study
bPapers from the same Netherlands study
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risk women, the risk of contralateral or primary breast
cancer was communicated to 38% of cancer patients and the
risk of ovarian cancer to 50% [22].
The survey found that patients preferred risk to be per-
sonalised and presented in general terms [22]. However,
risk was mostly communicated negatively in terms of harm,
as a lifetime risk and numerically or qualitatively and health
professionals rarely asked about preferred risk format or
existing understanding of risk [22].
Cognitive and emotional impact of communication
Recall and risk perception Eleven articles addressed recall
and risk perception [23–33]. Of these, three articles were
from the same study from the Netherlands [24–26]. Sig-
niﬁcant increase in knowledge was reported following pre-
test communication by face-to-face genetic counselling [23,
27, 29], group education [28] and written communication
[31, 32]. However, a signiﬁcant reduction in hereditary
cancer knowledge amongst breast cancer patients was
identiﬁed between pre- and post-test genetic counselling
[28, 29]. Low levels of accuracy of recall were observed
amongst cancer patients in the weeks following genetic
counselling [25, 33]. Similar ﬁndings were observed
amongst breast cancer patients (n= 248) 5 years after
genetic counselling when, although 75% of patients recalled
their genetic test result, no more than 30% of patients
accurately recalled the associated risks and likelihood of
inheritance [25]. The same study found that mirroring risk
reduced the accuracy of risk perception [24].
The only information provided by genetic counselling
that predicted risk perception and risk management
intentions concerned the genetic test result, the risk for
the patient and the risk for relatives [26]. Cancer patients
with a pathogenic variant who considered their cancer to be
less severe and who used positive coping styles rather than
avoidance strategies demonstrated more accurate risk
perception than other patients [24].
Understanding and interpretation Six studies addressed
understanding and interpretation [25, 34–38]. Amongst
patients found not to have a variant in a qualitative study,
interpretation of the result varied, with some believing with
certainty that they carried a pathogenic variant, some
believing that they did not and some expressing uncertainty
[34]. In a study of 248 patients receiving a pathogenic
variant or no variant detected result directly predicted
decisions about surgery or more frequent surveillance. All
other decisions made as a result of the test were based on
interpretation of risk rather than the actual communicated
risk [25]. In a qualitative study, patients with a pathogenic
variant were uncertain about which family members they
should inform about their genetic risk [35].Ta
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Communication about genetic testing with breast and ovarian cancer patients: a scoping review
A longitudinal survey found no difference in reported
understanding of the result or perceived breast cancer risk
between cancer patients who received a variant of uncertain
signiﬁcance (VUS) (n= 10) and those who did not have a
variant (n= 37) [36]. In a further qualitative study of 17
patients with a VUS, 77% interpreted the result as
pathogenic, despite factual recall of the result as not
informative. Of these, 50% underwent risk-reducing surgery
in the year following the result [37]. A qualitative study of
30 breast and ovarian cancer patients found that those who
misinterpreted a VUS result as good news experienced
elation or relief, whereas those who correctly understood
the result as inconclusive experienced a range of emotions,
including disbelief, acceptance, disappointment, anger or
frustration [35]. Patients who adopted more positive coping
styles had a better understanding of the risks associated with
a VUS [37].
A qualitative study of breast cancer patients interviewed
following pre-test genetic counselling prior to or after
deﬁnitive surgery found a lack of understanding about what
would be involved and misunderstanding about the
inevitability of genetic testing. Patients were unaware even
after genetic counselling of the utility of genetic testing and
surprised that testing might result in further surgery and
heightened emotions [38].
Anxiety and distress Nine studies addressed anxiety and
distress [23, 27, 28, 30–32, 36, 39, 40]. Pre-test commu-
nication did not have a negative impact on cancer-related
distress, anxiety or depression, intrusive thoughts, decisio-
nal conﬂict, family involvement in decision-making or
satisfaction amongst cancer patients in ﬁve of these studies
[23, 27, 30–32]. However, three studies found that anxiety,
depression and cancer-related distress were increased and
general health decreased amongst cancer patients and at-risk
women after disclosure of the genetic test result [28, 39,
40]. A longitudinal survey of 243 breast cancer patients
found that amongst those who over-estimated their risk of a
pathogenic variant at pre-test counselling, anxiety was
raised at post-test counselling [28]. A randomised long-
itudinal survey found that cancer-related distress and anxi-
ety was higher amongst patients diagnosed within a year of
genetic testing than those tested over a year from diagnosis
(p= .05) [39]. In a survey of breast cancer patients, no
differences were found in anxiety or psychological distress
between those who received a VUS and those who in whom
no variant was detected [36].
Patients’ experiences of communication
Four qualitative studies addressed patients’ experiences of
communication [34, 35, 37, 41]. Three studies found that
some patients tested after completing cancer treatment
experienced confusion and shock upon receiving genetic
test results [34, 35, 37]. A study of patients tested shortly
after diagnosis without pre-test genetic counselling found
that the emotional turmoil of the cancer diagnosis was
heightened by the difﬁculty of receiving and comprehend-
ing the information [41]. Patients who were distressed by
genetic test results that showed no variant was detected
coped by questioning the adequacy of testing, distrusting
the result and emphasising the difference between their
family history and other higher risk families [34].
Timing of pre-test communication
Ten studies addressed the timing of pre-test communication
[17, 18, 27, 29, 30, 32, 38, 41–43]. Pre-test communication
shortly after diagnosis was acceptable to most patients
studied and did not cause distress [17, 18, 27, 29, 30, 32,
42, 43]. Some patients were unprepared for the implications
of testing or did not understand the utility of the test [38,
42]. A qualitative study of 17 breast and ovarian cancer
patients tested shortly after diagnosis without prior genetic
counselling found that patients experienced shock, distress
and confusion [41].
Alternatives to face-to-face genetic counselling
Five studies addressed alternatives to face-to-face genetic
counselling [30–32, 41, 43]. Knowledge and satisfaction
were increased amongst patients who received pre-test
communication via group education [30] or written infor-
mation which aimed to supplement [30, 31] or replace
genetic counselling [32]. Amongst 161 breast cancer
patients who underwent genetic testing following written
and digital communication without face-to-face genetic
counselling, satisfaction with the amount and quality of pre-
test information was high with most stating they would
choose the same approach again and would recommend the
approach to other patients [44]. No differences were found
in psychological distress, quality of life or risk perception
amongst patients who did and did not receive face-to-face
pre-test genetic counselling [44]. A qualitative study with a
small sample of these same patients however highlighted
the need for support and counselling to increase under-
standing and empower decision-making [41].
Discussion
Prior to 2008, most studies of communication about genetic
testing for hereditary breast and ovarian cancer focused on
at-risk women. Later studies of communication with cancer
patients have mainly addressed genetic testing shortly after
diagnosis. Although many studies have focused on the
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cognitive and emotional impact of genetic counselling, few
have investigated patients’ information needs, the process
and content of the communication or patients’ experiences
of communication. Despite the increasing need to deliver
genetic testing within mainstream oncology, all but one of
the studies identiﬁed by this review involved genetics health
professionals only and all addressed communication in the
clinical genetics setting.
Although cancer patients expressed a need for simple,
cancer-focused, personalised information, the information
communicated about genetic testing is frequently difﬁcult to
understand [45] and does not always meet the needs of
patients. For patients with cancer, information is often
regarded as a method of reducing uncertainty and providing
a sense of personal control as well as enabling informed
decisions about treatment options [46, 47].
Genetic counselling of cancer patients focused on bio-
medical information-giving with less attention to psycho-
logical aspects. Studies of the process and content of genetic
counselling with at-risk women have identiﬁed a similar
focus [2, 45, 48–52]. In studies of communication by
oncology health professionals with cancer patients, an
individualised approach [6] and good communication skills
[7] have been identiﬁed as requirements for effective
communication.
Pre-test genetic counselling increased knowledge without
raising anxiety or cancer-related distress. Similar ﬁndings
have been observed following genetic counselling about
hereditary breast and ovarian cancer with at-risk individuals
[53, 54]. Amongst cancer patients, genetic counselling did
not inﬂuence risk perception. In contrast, systematic
reviews have concluded that genetic counselling improves
risk perception in individuals at risk of breast cancer [2, 55]
and other genetic conditions [56].
Genetic test results were misunderstood or mis-
interpreted, leading some patients to make inappropriate
decisions about surgery and hindering family communica-
tion. Previous studies found that women with cancer
understand their genetic risk in the context of their previous
cancer experience [57] and identiﬁed lack of understanding
of the risks and beneﬁts of genetic information as a barrier
to family communication [58, 59]. Amongst patients with a
VUS, there were conﬂicting ﬁndings with some patients
perceiving no difference in cancer risk and others perceiv-
ing the result to be a pathogenic variant. A lack of clear
understanding about the meaning of a VUS has also been
identiﬁed amongst breast cancer specialists [60].
There was an increase in anxiety, depression and cancer-
related distress following results disclosure, especially
amongst those who over-estimated their risk at pre-test
genetic counselling and those tested without face-to-face
genetic counselling. Increased cancer-related distress has
also been observed in studies of the psychological impact of
genetic testing amongst breast cancer patients following
results disclosure [52, 57].
The few studies that investigated cancer patients’
experiences of communication found that for patients who
were unprepared, unsupported or tested shortly after diag-
nosis without pre-test genetic counselling, the results dis-
closure was shocking, confusing and distressing. The
impact of lack of support on experiences of genetic coun-
selling has been highlighted for patients with and at risk of
cancer [61, 62].
Communication about genetic testing shortly after diag-
nosis was acceptable for most patients. Early studies found
high anxiety amongst women tested within 1 year of breast
cancer diagnosis [63] and concern amongst health profes-
sionals and patients about the timing of testing [64].
However, studies investigating actual and hypothetical
experiences of genetic testing shortly after diagnosis have
found that, for the most part, patients and health profes-
sionals consider this type of genetic testing to be acceptable
and desirable for decision-making if treatment options are
improved as a result [65, 66].
For many cancer patients, pre-test communication with-
out individual face-to-face genetic counselling may be
acceptable, although this review identiﬁed that some
patients need enhanced support and counselling. Other
studies have found no differences in knowledge, distress or
satisfaction amongst patients who have received genetics
communication within the clinical genetics setting via group
education [67] or video-conferencing [68].
This scoping review maps the current range of evidence
speciﬁc to health professionals’ communication about her-
editary cancer with cancer patients. This review should not
be considered a deﬁnitive review of the literature in this
ﬁeld as, consistent with the methodology, no quality
assessment was made. Due to the breadth of the studies
reviewed, some areas of research only include a few studies.
It is only possible to draw tentative conclusions about the
clinical implications from these ﬁndings.
The ﬁndings suggest that greater attention may be needed
to the psychological and supportive aspects of genetic
counselling for cancer patients. If pre-test communication is
increasingly to be provided via methods other than face-to-
face genetic counselling, the post-test genetic counselling
appointment may be the only opportunity for cancer
patients to interact with a genetics health professional.
Helping patients and families to adjust to a genetic diag-
nosis and facilitating dissemination of genetics information
within families will become increasingly important aspects
of the role of genetics health professionals. Patients with a
pathogenic variant and those with a VUS may need addi-
tional help to understand the implications of genetic test
results and support with decision-making about cancer
management and cancer risk management. The limited
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studies of experiences of communication suggest that some
patients may need enhanced counselling and support
throughout the genetic testing process. As genetic testing
becomes further integrated into mainstream oncology, it
will be increasingly important to investigate communication
about genetic testing by oncology health professionals and
to develop and evaluate new models of communicating
about genetic testing with cancer patients.
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